AIM ImmunoTech (NYSE:AIM) Issues Quarterly Earnings Results

AIM ImmunoTech (NYSE:AIMGet Free Report) released its earnings results on Thursday. The company reported ($0.12) earnings per share for the quarter, reports. AIM ImmunoTech had a negative return on equity of 191.38% and a negative net margin of 16,123.32%. The business had revenue of $0.04 million for the quarter.

AIM ImmunoTech Price Performance

NYSE AIM opened at $0.40 on Friday. The business has a fifty day moving average price of $0.44 and a two-hundred day moving average price of $0.44. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.68 and a current ratio of 1.14. AIM ImmunoTech has a fifty-two week low of $0.32 and a fifty-two week high of $0.75.

Insider Activity

In other news, CEO Thomas K. Equels purchased 75,758 shares of the company’s stock in a transaction dated Friday, March 15th. The stock was bought at an average cost of $0.33 per share, for a total transaction of $25,000.14. Following the purchase, the chief executive officer now owns 716,455 shares of the company’s stock, valued at $236,430.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Thomas K. Equels acquired 61,729 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average cost of $0.41 per share, for a total transaction of $25,308.89. Following the completion of the acquisition, the chief executive officer now directly owns 778,184 shares of the company’s stock, valued at approximately $319,055.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Thomas K. Equels acquired 75,758 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was bought at an average price of $0.33 per share, with a total value of $25,000.14. Following the completion of the acquisition, the chief executive officer now directly owns 716,455 shares of the company’s stock, valued at $236,430.15. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 335,603 shares of company stock worth $120,464. Insiders own 0.02% of the company’s stock.

AIM ImmunoTech Company Profile

(Get Free Report)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

Recommended Stories

Earnings History for AIM ImmunoTech (NYSE:AIM)

Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.